GSK and Sabin Signs an Exclusive Agreement to Advance the Development of Ebola and Marburg Vaccines

 GSK and Sabin Signs an Exclusive Agreement to Advance the Development of Ebola and Marburg Vaccines

Shots:

  • Sabin to get an exclusive technology license for all three vaccine candidates i.e, Ebola Zaire, Ebola Sudan and Marburg vaccines and patent rights related to vaccines
  • In 2013, GSK acquired three vaccines from the US NIH & Okairos. The candidates are based on GSK’s ChAd3 platform and were developed by GSK including P-II development of Ebola Zaire vaccine
  • Additionally, Sabin has collaborated with VRC at NIAID to advance ChAd3 Ebola and Marburg vaccines and has evaluated them in multiple trials in 5,000+ adults & 600+ children which demonstrated high immunogenicity among the population  

Click here to­ read full press release/ article | Ref: GSK | Image: Boston Africa

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post